Dyspareunia, Genitourinary Syndrome of Menopause, Menopause Related Conditions, Quality of Life, Sexual Function, Urinary Incontinence, Urgency-frequency, Vaginal Dryness, Vulvar Atrophy, Vulvovaginal Signs and Symptoms, Women´s Health
Conditions
Keywords
Genitourinary Syndrome of Menopause, Vulvovaginal Signs and Symptoms, Patient Reported Outcome Measures, Quality of Life, Day-to-Day Impact of Vaginal Ageing, Women´s Health
Brief summary
The goal of this clinical trial is to improve the management of Genitourinary syndrome of menopause (GSM) to preliminary assess safety and effectivity of a novel hormone-free mucosa composition (XCMIM20m) applied topically to the vulvovaginal area. Symptoms of vaginal atrophy will be compared before and after 8 weeks of use of the tested gel with the Day-to-Day Impact of Vaginal Aging (DIVA) PROMs questionnaire to assess changes impact of GSM symptoms.
Detailed description
The high prevalence of the Genitourinary Syndrome of the Menopause (GSM) previously known as vulvovaginal atrophy, atrophic vaginitis or urogenital atrophy, does not correlate with the fact that up until today GSM is still hugely underreported, underdiscussed, underdiagnosed as well as undertreated. Postmenopausal women suffering from symptoms of GSM will be recruited after a routine visit at a Women's Unit at a General Hospital. The participants will self-assess their symptoms with the use of the Day-to-Day impact of Vaginal Aging (DIVA) questionnaire at baseline and after 8 weeks of use of the tested product. Self-assessment with PROMs will allow to obtain a greater knowledge of the physical and emotional state of patients as well as to deliver valuable information to women. Criteria for a successful outcome will be if the use of the hormone-free agent is well accepted and if symptoms and quality of life improve after 8 weeks of intervention. Daily dosage of XCMIM20m ((2-(trimethylazaniumyl) acetate; (2R,3R,4S)-pentane-1,2,3,4,5-pentol; Hexadecanoic acid; (9Z, 12Z)-octadeca-9,12-dienoic acid; octadecanoic acid; (Z)-hexadec-9-enoic acid; (Z)-octadec-9-enoic acid)) will be 2 ml of total product, divided in two applications of 1 ml every 12 hours, preferably morning and bedtime. To be spread topically onto the vulvar area, including the vaginal introitus. The gel will be further applied before sexual intercourse. No intravaginal applicator will be used as the agent will be manually applied directly onto the vulvar area from a 50 ml airless pump dispenser. Four pump applications from the pump dispenser are equivalent to 1ml of tested gel. Adverse effects, such as allergic reaction, skin irritation, itching, discomfort, yeast infection, or any other, will be collected and if so, a detailed description and follow-up of the problem will be noted.
Interventions
DEVICEHormone-free vulvovaginal gel with the tested composition XCMIM20m
Management of GSM in post-menopausal women will be measured with the combination of the application of the hormone-free vulvovaginal gel along the 8 weeks of the study and the use of a PROMs questionnaire. PROMS questionnaire will be delivered to the women at baseline and at the end of the study. Daily living quality of life domains of "activities of daily living", "emotional well-being", "sexual functioning", "self-perception and body image" will be evaluated.
Sponsors
Mucosa Innovations, S.L.
Hospital de La Luz
Hospital Universitario Fundación Jiménez Díaz
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
40 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Patient has to have at least one symptom of GSM or suffer from symptoms related to vulvovaginal atrophy (as evidenced by gynecological examination with a Vaginal Health Index ≤15). * Patient must be postmenopausal with at least 1 year without a menstrual period. * Patient must consider that her quality of life is affected by GSM symptoms * Patient not followed due to any gynecological disease. * All participants must be able to understand and to fill in the self-reported questionnaires.
Exclusion criteria
* Patients that do not want to fill the questionnaire, especially the questions that address sexual functioning. * Participants that use any oral products containing hormones or estrogen receptor modulators for the past 8 weeks, nor vaginal topical hormone products within 4 weeks, neither prescription nor non-prescription therapies for GSM, including topical vaginal non-hormonal lubricants or moisturizers for the last week. * Patients with history of vulvar, vaginal and/or cervical malignancy. * Patients having received radiotherapy treatment in the pelvic and/or genital region. * Patients with any type of disease that causes alteration of collagenogenesis. * Patients that use cytotoxic drugs leading to mucositis and alterations of tissue regeneration in the last 6 months. * Patients having received laser and/or radiofrequency treatment for handling genital atrophy or other pelvic floor dysfunctions. * Patients with active urinary and/or genital tract infection. * Patients with history of malignant neoplasm of the urinary system. * Patients with severe stress urinary incontinence (Sandvik test score equal to or greater than 8). * Patients with diagnosis of pelvic organ prolapse grade III or higher according to the POP-Q classification. * Patients with medical or surgery history that, at the investigator's discretion, does not allow participation in the study. * Patients with any other condition that, at the investigator's discretion, implies that the patient is unable to understand the implication of participating in the study and/or following the established procedures.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Changes in GSM symptoms impact on quality of life domains after the intervention | Eight weeks of use of the tested product. | Difference of magnitude of complaint by domain after 8 weeks of use of the tested product compared with baseline with the use of the PROMs questionnaire. The PROMs questionnaire will be the 23-item DIVA questionnaire comprising four domain scales: activities of daily living; emotional well-being; sexual functioning; and self-concept and body image. Each 23 items will be scored from 0 (meaning lowest impact/best quality of life) to 4 (meaning highest impact/worst quality of life). Total scores domain by domain will be assessed by calculating the average of scores for each item; higher scores will be interpreted as greater impact of GSM symptoms on women's quality of life and adscribed to each domain. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Changes in the most affected women's quality of life domain after the intervention | Eight weeks of use of the tested product. | Comparison in number of answers obtained for each score (0 to 4), domain by domain, at baseline and after 8 weeks of the use of the tested product assessed by the PROMs questionnaire. The PROMs questionnaire will be the 23-item DIVA questionnaire comprising four domain scales: activities of daily living; emotional well-being; sexual functioning; and self-concept and body image. Each 23 items will be scored from 0 (meaning lowest impact/best quality of life) to 4 (meaning highest impact/worst quality of life). Total scores domain by domain will be assessed by calculating the average of scores for each item; higher scores will be interpreted as greater impact of GSM symptoms on women's quality of life and adscribed to each domain. |
Countries
Spain
Contacts
CONTACTJorge Rodríguez-Vilaboa
PRINCIPAL_INVESTIGATORManuel Albi, MD, PhD
Hospital La Luz
Outcome results
None listed